| 3 | | - | House File 383, p. 2 psilocybin, also known as COMP 360, or any other trade name approved by the United States food and drug administration. ______________________________ PAT GRASSLEY Speaker of the House ______________________________ AMY SINCLAIR President of the Senate I hereby certify that this bill originated in the House and is known as House File 383, Ninety-first General Assembly. ______________________________ MEGHAN NELSON Chief Clerk of the House Approved _______________, 2025 ______________________________ KIM REYNOLDS Governor |
|---|
| 3 | + | H.F. 383 Section 1. Section 124.201, Code 2025, is amended by adding 1 the following new subsection: 2 NEW SUBSECTION . 5. a. Notwithstanding section 124.204, 3 subsection 4, a drug that contains the pharmaceutical 4 composition of crystalline polymorph psilocybin, also known as 5 COMP 360, or any other trade name approved by the United States 6 food and drug administration, shall be immediately removed 7 from schedule I under section 124.204, subsection 4, paragraph 8 s , upon its approval by the United States food and drug 9 administration and rescheduled based upon the recommendations 10 of the United States food and drug administration and its 11 listing in the federal Controlled Substances Act, 21 U.S.C. 12 812, and 21 C.F.R. 1308.14. 13 b. Immediately upon the rescheduling of the drug under 14 paragraph a , it shall be lawful to prescribe, distribute, and 15 market the pharmaceutical composition of crystalline polymorph 16 psilocybin, also known as COMP 360, or any other trade name 17 approved by the United States food and drug administration. 18 EXPLANATION 19 The inclusion of this explanation does not constitute agreement with 20 the explanations substance by the members of the general assembly. 21 This bill relates to the controlled substance crystalline 22 polymorph psilocybin. 23 Current law categorizes the controlled substance psilocybin 24 as a schedule I, hallucinogenic substance (Code section 25 124.201(4)(s)). 26 The bill provides that notwithstanding Code section 27 124.204(4), a drug that contains the pharmaceutical composition 28 of crystalline polymorph psilocybin shall be immediately 29 removed from schedule I upon its approval by the United 30 States food and drug administration and rescheduled based 31 upon the recommendations of the United States food and drug 32 administration and its listing in the federal Controlled 33 Substances Act. 34 The bill provides that upon the rescheduling of psilocybin, 35 -1- LSB 1725HV (1) 91 as/js 1/ 2 |
|---|